文献速递外周动脉疾病

衰弱与年龄对血管内治疗患者临床结局的影响

Impact of Frailty and Age on Clinical Outcomes in Patients Who Underwent Endovascular Therapy.
PubMed 文献 · J Endovasc Ther · 2021-12-30

本研究基于I-PAD注册研究,纳入2015年8月至2016年8月长野县7家机构连续接受血管内治疗的335例患者,按年龄(≥75岁或<75岁)和临床衰弱量表(CFS≥5为衰弱)分为4组分析323例。中位随访2.7年,衰弱组无主要不良心脑血管及肢体事件(MACLE)生存率显著低于无衰弱组,多因素分析显示衰弱与MACLE发生独立相关。作者认为CFS定义的衰弱可能是EVT患者MACLE的预测因素。

要点

  • 衰弱(CFS≥5)与EVT术后MACLE发生独立相关,年龄本身不是独立预测因素。
  • 老年衰弱组无MACLE生存率34.9%,老年无衰弱组55.7%,差异有统计学意义(p<0.001)。
  • 作者建议以衰弱而非年龄来考量PAD患者的治疗指征。

核心结论

  • CFS定义的衰弱可能是接受EVT的PAD患者MACLE发生的预测因素。
  • 作者认为,通过关注衰弱而非年龄来考量PAD患者的治疗指征,可能有助于审视EVT策略是否合适,并管理患者和照护者对功能结局改善的预期。
  • 作者期待进一步研究探讨EVT后衰弱变化是否改变预后。

研究设计与样本

  • 研究为I-PAD注册研究,纳入2015年8月至2016年8月长野县7家机构连续接受EVT的335例患者。
  • 将323例患者按年龄和衰弱状态分为4组:老年衰弱组(年龄≥75岁,CFS≥5)、老年无衰弱组(年龄≥75岁,CFS≤4)、年轻衰弱组(年龄<75岁,CFS≥5)、年轻无衰弱组(年龄<75岁,CFS≤4)。
  • 主要终点为MACLE,定义为心血管死亡、心肌梗死、卒中、心力衰竭住院、大截肢和血运重建的复合终点;次要终点为心血管死亡。
  • 中位随访期为2.7年。

主要发现

  • 老年衰弱组、老年无衰弱组、年轻衰弱组、年轻无衰弱组的无MACLE生存率分别为34.9%、55.7%、35.4%、63.0%(p<0.001)。
  • 四组全因死亡生存率分别为43.5%、73.4%、50.7%、90.9%(p<0.001)。
  • 原文报告老年衰弱组无MACLE生存率显著高于年轻无衰弱组(55.7% vs 35.4%,p=0.01),原文此处写作老年衰弱组与年轻无衰弱组比较,按上下文应为老年无衰弱组与年轻衰弱组比较。
  • 多因素分析显示衰弱与MACLE发生独立相关。

关键数值与推荐

  • 衰弱定义为临床衰弱量表(CFS)评分≥5分。
  • 老年定义为年龄≥75岁。
  • MACLE定义为心血管死亡、心肌梗死、卒中、心力衰竭住院、大截肢和血运重建的复合终点。

临床怎么用

  • 作者认为,通过关注衰弱而非年龄来考量PAD患者的治疗指征,可能有助于审视EVT策略是否合适,并管理患者和照护者对功能结局改善的预期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Information on the relationship between frailty and the outcome of endovascular therapy (EVT) in elderly patients with lower extremity peripheral artery disease (PAD) is scarce. This study aimed to reveal the impact of frailty on the prognosis of super-elderly patients who underwent EVT. MATERIALS AND METHODS: From August 2015 to August 2016, 335 consecutive patients who underwent EVT were enrolled in the I-PAD registry from 7 institutes in Nagano prefecture. Among them, we categorized 323 patients into 4 groups according to age and the presence or absence of frailty as follows: elderly with frailty (age ≥ 75, Clinical Frailty Scale [CFS] ≥ 5), elderly without frailty (age ≥ 75, CFS ≤ 4), young with frailty (age < 75, CFS ≥ 5), and young without frailty (age < 75, CFS ≤ 4); we analyzed them accordingly. The primary endpoints were major adverse cardiovascular and limb events (MACLE), defined as a composite of cardiovascular death, myocardial infarction, stroke, admission for heart failure, major amputation, and revascularization. The secondary endpoint was cardiovascular death. RESULTS: The median follow-up period was 2.7 years. In the elderly with frailty, elderly without frailty, young with frailty, and young without frailty groups, the freedom rates from MACLE were 34.9%, 55.7%, 35.4%, and 63.0%, respectively (p<0.001) and from all-cause death were 43.5%, 73.4%, 50.7%, and 90.9%, respectively (p<0.001). The freedom rates from MACLE were significantly higher among elderly patients with frailty than among young patients without frailty (55.7% vs 35.4%, p=0.01). In multivariate analysis, frailty was independently associated with MACLE incidence. CONCLUSION: Frailty as defined by CFS might be a predictor of MACLE incidence in patients with PAD who underwent EVT. By considering treatment indications for patients with PAD by focusing on frailty rather than age, we may examine whether EVT policies are appropriate and manage patient and caregiver expectations for potential improvement in functional outcomes. Further studies are expected to investigate whether changes in frailty after EVT change prognosis.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Nishikawa K, Ebisawa S, Miura T, et al. Impact of Frailty and Age on Clinical Outcomes in Patients Who Underwent Endovascular Therapy. J Endovasc Ther. 2021. PMID: 34969317. doi:10.1177/15266028211067729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。